- freely available
Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers
AbstractRecent clinical trials of small interfering RNAs (siRNAs) highlight the need for robust delivery technologies that will facilitate the successful application of these therapeutics to humans. Arguably, cell targeting by conjugation to cell-specific ligands provides a viable solution to this problem. Synthetic RNA ligands (aptamers) represent an emerging class of pharmaceuticals with great potential for targeted therapeutic applications. For targeted delivery of siRNAs with aptamers, the aptamer-siRNA conjugate must be taken up by cells and reach the cytoplasm. To this end, we have developed cell-based selection approaches to isolate aptamers that internalize upon binding to their cognate receptor on the cell surface. Here we describe methods to monitor for cellular uptake of aptamers. These include: (1) antibody amplification microscopy, (2) microplate-based fluorescence assay, (3) a quantitative and ultrasensitive internalization method (“QUSIM”) and (4) a way to monitor for cytoplasmic delivery using the ribosome inactivating protein-based (RNA-RIP) assay. Collectively, these methods provide a toolset that can expedite the development of aptamer ligands to target and deliver therapeutic siRNAs in vivo.
Share & Cite This Article
Export to BibTeX | EndNote
MDPI and ACS Style
Hernandez, L.I.; Flenker, K.S.; Hernandez, F.J.; Klingelhutz, A.J.; McNamara, J.O.; Giangrande, P.H. Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers. Pharmaceuticals 2013, 6, 295-319.View more citation formats
Hernandez LI, Flenker KS, Hernandez FJ, Klingelhutz AJ, McNamara JO, Giangrande PH. Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers. Pharmaceuticals. 2013; 6(3):295-319.Chicago/Turabian Style
Hernandez, Luiza I.; Flenker, Katie S.; Hernandez, Frank J.; Klingelhutz, Aloysius J.; McNamara, James O.; Giangrande, Paloma H. 2013. "Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers." Pharmaceuticals 6, no. 3: 295-319.